Publications Archive

Nobody dares to stop clinical research, not even COVID-19

In the global health emergency caused by the SARS-CoV-2 virus, clinical trial management has proven critical for the pharmaceutical industry and healthcare professionals. This article discussed the importance of adopting measures which, primarily, prioritize patient safety and data validity, as well as the use of contingency measures such as telemedicine, virtual medical examination and remote monitoring. All with the goal of ensuring that clinical cancer research continues during the SARS-CoV-2 pandemic.

DOI: 10.1038/s41523-021-00249-1

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade

The objective of this study was to identify HER2-positive breast tumours that present a high sensitivity to anti-HER2 therapies, and in which the use of chemotherapy could therefore be avoided. Tumours with intrinsic HER2-enriched subtype and high HER2 RNA expression are more sensitive to anti-HER2 therapies.

DOI: 10.1093/jnci/djz042


The PAMELA phase II clinical trial is a study that evaluated which HER2-positive localized breast cancer patients might benefit from a de-escalation in treatment intensity. This study demonstrated that patients with the HER2-enriched subtype benefited most from exclusive treatment with a dual HER2 blockade of trastuzumab and lapatinib.

DOI: 10.1016/S1470-2045(17)30021-9

HER2-low breast cancer: clinical and pathological overview

This review discussed the possibility of treating breast tumours with low HER2 expression with anti-HER2 therapies and proposed an algorithm to define this type of tumour, which means rethinking the traditional classification of breast tumours as HER2-positive or HER2-negative.

DOI: 10.1200/JCO.19.02488

Improving global access to anticancer drugs

This article outlined the factors that cause disparities in cancer survival between and within countries, such as limited access to adequate diagnosis, essential cancer drugs and high-quality care, exposing possible strategies to address access issues, including universal health coverage for essential cancer drugs, fairer approaches to setting the price of cancer drugs, reducing development costs, optimizing regulation and improving equity in the global supply chain.


Eribulin plus Balixafortide Phase 1

This phase I clinical trial confirmed that the antitumour activity of the combination of the CXCR4 inhibitor balixafortide with eribulin appears superior to that reported with eribulin monotherapy in previous studies, with a favourable toxicity profile. This combination is currently being evaluated in a phase III clinical study (FORTRESS).

DOI: 10.1016/S1470-2045(18)30147-5

New approach to cancer therapy based on a new molecular classification of cancer

This groundbreaking paper proposed a different approach to cancer classification with important implications for both treatment and basic, translational and clinical research. In the paper, it was postulated that cancers with multiple organs of origin, but with similar molecular traits, should be treated in the same way.

DOI: 10.3322/caac.21211


The KEYNOTE 522 phase III clinical trial is the first randomized clinical trial to confirm an increased pathologic complete response rate with the addition of pembrolizumab immunotherapy to neoadjuvant chemotherapy treatment in patients diagnosed with stage II and III triple-negative breast cancer. Approval of pembrolizumab in this group of patients is being evaluated by regulatory agencies based on the results of this study.

DOI: 10.1056/NEJMoa1910549


The Destiny Breast-01 phase II clinical trial demonstrated the impressive antitumour activity of the anti-HER2 therapy trastuzumab deruxtecan in extensively pretreated HER2-positive metastatic breast cancer patients. This clinical trial led to the approval of trastuzumab deruxtecan in the US and Europe for this patient group. It is the first time in history that a drug has been approved in this context based on the results of a phase II study.

DOI: 10.1056/NEJMoa1914510

Bienvenidos a International Breast Cancer Center, el primer centro hiperespecializado en cáncer de mama de España.

Si te acaban de diagnosticar un cáncer de mama, si estás siguiendo un tratamiento, si quieres saber más sobre esta enfermedad porque tienes dudas, miedo e incertidumbre, no estás sola. El equipo de International Breast Cancer Center, con más de quince años de experiencia en la investigación  y el tratamiento de este tipo de cáncer, te quiere acompañar.

Un equipo de oncólogos, radiooncólogos, cirujanos oncológicos, patólogos, radiólogos, psiconcólogos y demás profesionales, trabajamos juntos para que tu tratamiento sea tan particular como tú, para acompañaros a ti y a tu familia y entorno de forma personalizada, con comprensión y respeto, durante todo el camino.

Quizá no te sientes preparada para afrontar este proceso, pero seguro que te tranquiliza saber que nosotros sí lo estamos. Porque no paramos nunca de avanzar. Y lo hacemos por ti.

Equipo IBCC